Randox Laboratories's second biochip for drugs of abuse (DoA) screening simultaneously tests for six opioid analgesics including Fentanyl, as well as Ketamine, LSD, Methaqualone and Ecstasy (MDMA)
The release of Randox's DoA II array follows the success of the DoA Array I for barbiturates, amphetamines, cocaine, opiates and cannabinoids.
Each 9x9mm biochip contains an array of ten discrete test regions of immobilised antibodies specific to different drugs of abuse.
A CCD (charge-coupled device) camera detects the chemiluminescent signal generated by each test region and advanced image-processing software reads all ten test results simultaneously.
Both arrays include an eleventh test, creatinine, to identify adulterated urine samples.
Three different biochips are designed for DoA Array I, each optimised for a different matrix: blood, urine and oral fluid.
DoA Array II is available for urine screening; blood and oral fluid biochips currently in development.
The fully automated evidence analyser offers a rapid, consistent and cost-effective system for high-throughput drugs of abuse screening.
The semi-automated Evidence Investigator is designed for low-throughput screening and research applications.
